NEW YORK (GenomeWeb) – The National Cancer Institute this month said that it has renewed a program under which it will fund the use of biosamples obtained through the Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) trial in order to advance research into the etiology and early detection of cancer.

The NCI said it will support a wide range of cancer research including biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.